CA2417874A1 - Use of ox-2 inhibitors for the treatment of cancer - Google Patents
Use of ox-2 inhibitors for the treatment of cancer Download PDFInfo
- Publication number
- CA2417874A1 CA2417874A1 CA002417874A CA2417874A CA2417874A1 CA 2417874 A1 CA2417874 A1 CA 2417874A1 CA 002417874 A CA002417874 A CA 002417874A CA 2417874 A CA2417874 A CA 2417874A CA 2417874 A1 CA2417874 A1 CA 2417874A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- protein
- molecule
- effective amount
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims abstract 10
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims abstract 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 3
- 206010027476 Metastases Diseases 0.000 claims abstract 2
- 230000009401 metastasis Effects 0.000 claims abstract 2
- 230000004565 tumor cell growth Effects 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 abstract 3
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods and compositions for regulating tumor growth are disclosed. For reducing tumor growth, agents that inhibit OX-2 are administered. Such metho ds are useful in treating cancer. For enhancing tumor growth, an OX-2 protein o r a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in studying cancer and/or tumor metastasis.
Claims (9)
1. A use of an effective amount of an agent that inhibits an OX-2 protein to prepare a medicament to prevent, inhibit or reduce tumor cell growth.
2. A use according to claim 1 wherein the agent is a molecule that binds the OX-2 protein.
3. A use according to claim 2 wherein the agent is an antibody.
4. A use according to claim 1 wherein the agent is an antisense oligonucleotide that is complimentary to a nucleic acid sequence from an OX-2 gene.
5. A pharmaceutical composition for use in preventing, inhibiting or reducing tumor cell growth comprising an effective amount of an agent that inhibits OX-2 in admixture with a suitable diluent or carrier.
6. A composition according to claim 5 wherein the agent is a molecule that binds the OX-2 protein.
7. A composition according to claim 6 wherein the molecule is an antibody.
8. A composition according to claim 5 wherein the agent is an antisense oligonucleotide that is complimentary to a nucleic acid sequence from an OX-2 gene.
9. A use of an effective amount of an OX-2 protein to prepare a medicament to induce tumor cell growth or metastasis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22272500P | 2000-08-03 | 2000-08-03 | |
| US60/222,725 | 2000-08-03 | ||
| PCT/CA2001/001111 WO2002011762A2 (en) | 2000-08-03 | 2001-07-30 | Methods and compositions for modulating tumor growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2417874A1 true CA2417874A1 (en) | 2002-02-14 |
| CA2417874C CA2417874C (en) | 2012-10-02 |
Family
ID=22833418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2417874A Expired - Fee Related CA2417874C (en) | 2000-08-03 | 2001-07-30 | Use of ox-2 inhibitors for the treatment of cancer |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001278338A1 (en) |
| CA (1) | CA2417874C (en) |
| WO (1) | WO2002011762A2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002223338B2 (en) * | 2000-11-22 | 2007-06-07 | Trillium Therapeutics Inc. | Truncated CD200 |
| AU2004217434B2 (en) * | 2000-12-08 | 2010-08-26 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US9249229B2 (en) | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| CA2436595C (en) | 2000-12-08 | 2011-11-08 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
| US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| CA2478803A1 (en) * | 2002-03-15 | 2003-09-25 | Schering Corporation | Methods of modulating cd200 receptors |
| WO2004060295A2 (en) * | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| AU2012211347B9 (en) * | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| TW200804422A (en) | 2006-01-12 | 2008-01-16 | Alexion Pharma Inc | Antibodies to OX-2/CD200 and uses thereof |
| JP2010534242A (en) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Methods and compositions for treating autoimmune diseases |
| IN2012DN06309A (en) | 2010-01-11 | 2015-09-25 | Alexion Pharma Inc | |
| EP2534178A4 (en) | 2010-02-11 | 2013-08-07 | Alexion Pharma Inc | Therapeutic methods using an ti-cd200 antibodies |
| WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
| JP7261379B2 (en) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | Anti-PD-L1 antibody |
| US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| US12139533B2 (en) | 2017-12-20 | 2024-11-12 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-CD200 antibodies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE319825T1 (en) * | 1997-11-07 | 2006-03-15 | Trillium Therapeutics Inc | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION |
-
2001
- 2001-07-30 AU AU2001278338A patent/AU2001278338A1/en not_active Abandoned
- 2001-07-30 CA CA2417874A patent/CA2417874C/en not_active Expired - Fee Related
- 2001-07-30 WO PCT/CA2001/001111 patent/WO2002011762A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002011762A3 (en) | 2003-03-13 |
| WO2002011762A2 (en) | 2002-02-14 |
| CA2417874C (en) | 2012-10-02 |
| AU2001278338A1 (en) | 2002-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2417874A1 (en) | Use of ox-2 inhibitors for the treatment of cancer | |
| ATE334657T1 (en) | INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODEOXYNUCLEOTIDES | |
| GEP20053424B (en) | Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors | |
| WO2000063364A3 (en) | Methods and compositions for inhibiting the function of polynucleotide sequences | |
| EP1379251A4 (en) | Inhibitors of akt activity | |
| Feldman et al. | Binding of α2-macroglobulin to hepatocytes: mechanism of in vivo clearance | |
| GB2370774A (en) | Anti-infective compositions for treating disordered tissue such as cold sores | |
| WO2004076644A3 (en) | A composition for delivering an agent to a target cell and uses thereof | |
| BR0109517A (en) | Synergistic Methods and Compositions for Treating Cancer | |
| BR9710768A (en) | Compound composition and processes for the treatment of bacterial infections in a host mammal in need of such treatment and for the preparation of 6-0-metilerithromycin form i | |
| BG106020A (en) | Inhibitors of impdh enzyme | |
| NZ515964A (en) | A method for the prophylaxis and/or treatment of medical disorders | |
| EA200500300A1 (en) | CYTOTOXIC AGENTS CONTAINING NEW STRONGLY ACTIVE TAXANS, AND THEIR THERAPEUTIC APPLICATION | |
| BR9807418A (en) | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | |
| NZ596981A (en) | Compositions and methods for the treatment of tumor of hematopoietic origin | |
| DE69907419D1 (en) | Antitumorwirkstoffe | |
| Dalbies et al. | Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum (II)-modified single-stranded oligonucleotides | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| UA81634C2 (en) | Pharmaceutical compoosition containing urease for inhibiting cancer cell growth | |
| WO2002100343A3 (en) | N-terminally truncated galectin-3 and antibodies for treating cancer | |
| BRPI0414812A (en) | method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancer | |
| ATE332369T1 (en) | INHIBITION OF CHRONIC MYELOGENE LEUKEMIC CELL GROWTH BY ANTISENSE OLIGONUCLEOTIDES TARGETED AT GRB2 | |
| IL172538A0 (en) | Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof | |
| AU2001220255A1 (en) | Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferationof cancer cell using the expression vector | |
| MXPA02010813A (en) | Bis (n,n bis (2 haloethyl)amino) phosphoramidates as antitumor agents. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140730 |